An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Royalty Pharma plc (Nasdaq: RPRX) will announce its first quarter 2024 financial results on May 9, 2024. The company will host a conference call and webcast at 8:00 a.m. Eastern Time on the same day.
Royalty Pharma plc (Nasdaq: RPRX) annuncerà i risultati finanziari del primo trimestre del 2024 il 9 maggio 2024. La società terrà una conferenza telefonica e un webcast alle 8:00, ora della costa orientale, lo stesso giorno.
Royalty Pharma plc (Nasdaq: RPRX) anunciará sus resultados financieros del primer trimestre de 2024 el 9 de mayo de 2024. La empresa realizará una llamada de conferencia y una transmisión web a las 8:00 a.m. hora del Este, el mismo día.
로열티 파마 plc (나스닥: RPRX)는 2024년도 1분기 재무 결과를 2024년 5월 9일에 발표할 예정이다. 회사는 같은 날 동부 표준시 오전 8시에 컨퍼런스 콜과 웹캐스트를 주최할 것이다.
Royalty Pharma plc (Nasdaq : RPRX) annoncera ses résultats financiers pour le premier trimestre 2024 le 9 mai 2024. La société organisera une conférence téléphonique et une webdiffusion à 8h00, heure de l'Est, le même jour.
Royalty Pharma plc (Nasdaq: RPRX) wird seine Finanzergebnisse für das erste Quartal 2024 am 9. Mai 2024 bekannt geben. Das Unternehmen wird am selben Tag um 8:00 Uhr Eastern Time eine Telefonkonferenz und einen Webcast veranstalten.
Positive
None.
Negative
None.
NEW YORK, April 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2024 financial results on Thursday, May 9, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day.
Conference Call Information
Please visit the “Investors” page of the company’s website at https://www.royaltypharma.com/investors/events/ to obtain conference call information and to view the live webcast. A replay of the conference call and webcast will be archived on the company's website for at least 30 days.
About Royalty Pharma
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 14 development-stage product candidates. For more information, visit www.royaltypharma.com.
Royalty Pharma Investor Relations and Communications
When will Royalty Pharma announce its first quarter 2024 financial results?
Royalty Pharma will announce its first quarter 2024 financial results on May 9, 2024.
What is the ticker symbol for Royalty Pharma?
The ticker symbol for Royalty Pharma is RPRX.
Where can I find information about the conference call and webcast for Royalty Pharma's financial results?
You can visit the 'Investors' page of Royalty Pharma's website at https://www.royaltypharma.com/investors/events/ to obtain conference call information and view the live webcast.
Will there be a replay of the conference call and webcast?
Yes, a replay of the conference call and webcast will be archived on Royalty Pharma's website for at least 30 days.
royalty pharma is the industry leader in acquiring revenue-producing intellectual property – principally royalty interests in marketed and late stage biopharmaceutical products with $13 billion in assets. since inception in 1996, royalty pharma and its predecessors have invested approximately $5.8 billion to assemble a leading portfolio of royalty interests in pharmaceutical and biopharmaceutical products. royalty pharma’s strategy has been to acquire royalty interests in leading pharmaceutical and biotechnology products and hold these interests as part of a portfolio, seeking to diversify its revenue base across product and therapeutic classes. royalty pharma captures many of the strong and predictable aspects of the pharmaceutical industy while limiting the typical risks of biopharmaceutical companies. royalty pharma currently owns a diversified portfolio of royalty interests in several high- quality blockbuster biopharmaceutical products, including abbott’s humira®, j&j/merck’s remi
